Related Case Studies
A Comprehensive Launch Strategy Leads to Broad Access
A biopharmaceutical company was in the midst of bringing its first product to market with breakthrough therapy designation. The PDUFA date was fast approaching, and their small team needed guidance to steer them through the complicated access and reimbursement landscape.
A Novel Therapy Seeks to Support Physician Reimbursement
An emerging pharmaceutical manufacturer sought FDA approval for a first-in-class therapy with potential to offer significant clinical improvement for patients with small cell lung cancer. However, there was concern about reimbursement. For a subset of patients, the therapy had to be administered in an in-patient setting, and current MS-DRG bundled payments were not priced to appropriately cover this type of administration. Without appropriate reimbursement, providers would be less likely to incur the risk in prescribing the novel therapy and access for patients would be severely limited.
The Case is Made for New CPT Codes
A ground-breaking medical device, although recognized by major clinical compendia, was lacking the appropriate Current Procedural Terminology (CPT) codes. This created hesitancy among providers, who feared they would not be reimbursed or prescribing this supportive care technology for their patients.
View All Case Studies
- Assessing Market Potential
- MSL Trainings
- Conference Engagement Strategy
- KOL Development
- Guideline Advocacy Strategy
- Clinical Guideline Strategy
- Engaging Community and Academic Physicians in Preparation for Product Launch
- Understanding the Patient Journey and Pain Points in Diagnosis
- Collecting KOL Insights Into Trial Design
- Healthcare Policy Changes Interpreted in Real-Time
- A Comprehensive Launch Strategy Leads to Broad Access
- Understanding the European Market
- Insight Into a New Therapeutic Landscape
- Strategizing a Change in a Company’s Focus
- A Novel Therapy Seeks to Support Physician Reimbursement
- The Case is Made for New CPT Codes
- A Successful Transition from Europe to the US Market
- A First of its Kind Approval Changes the Way We Think About Access